London,
United Kingdom, October 21, 2004
IMPAC Medical Systems,
(NASDAQ:IMPCE), a leading provider of information technology
solutions for oncology care, announced today multiple new
radiation oncology installations throughout the United Kingdom and
Europe. Since expanding its direct operations outside of North
America in 2002, the benefits of IMPAC’s comprehensive practice
management and image-enabled electronic patient record system have
become recognized as the industry standard with multiple new
installations in prestigious cancer centres throughout the world.
Several recent European radiation oncology installations include
Mannheim Medical Center (Mannheim, Germany), Royal Wolverhampton
NHS Trust (Wolverhampton, England), North Middlesex University
Hospital NHS Trust (London, England), The Christie Hospital NHS
Trust (Manchester, England), Trinity College School of
Radiotherapy (Dublin, Ireland), Erasmus MC University Medical
Center (Rotterdam, The Netherlands), University Medical Centre
Utrecht, (Utrecht, The Netherlands), Mälar Hospital (Eskilstuna,
Sweden), MD Anderson Espana (Madrid, Spain), Hospital CUF
Descobertos (Lisbon, Portugal), Institute of Oncology (Ljubljana,
Slovenia), and Ege University (Izmir, Turkey).
According to Professor Frederik Wenz, M.D., department of
radiation oncology, Mannheim Medical Center, Mannheim, Germany
“When looking for an electronic patient record system we needed to
ensure there was full integration with the different makes of
radiotherapy equipment used in our facility. The IMPAC system
integrated all of our multi-vendor equipment and aggregated
critical patient data all into a single, complete picture of
patient care that is accessible to our staff wherever and whenever
they need it.”
IMPAC’s comprehensive oncology information system was designed to
help radiotherapy centres manage the entire spectrum of critical
patient data with process automation tools that improve process
efficiencies while reducing the risks of medical error. David
Auerbach, president of IMPAC’s International Operations stated
“IMPAC is thrilled that the benefits of our solutions are being
recognized on a global level and have proven to improve patient
care and enhance provider productivity.”
Professor Wenz added, “Prior to IMPAC our department maintained
many independent schedules for various resources throughout the
clinic. IMPAC has allowed us to combine these schedules into a
single system, dramatically improving the clinic’s efficiency.
Since implementing the IMPAC system, our wait times have been
reduced from almost eight weeks to virtually nothing right now.”
Ernie Dalton, head of medical physics with the Royal Wolverhampton
NHS Trust in Wolverhampton, England, stated “While IMPAC’s
independent connectivity to linear accelerators, imaging devices,
and treatment planning systems allows us the flexibility to
integrate best-of-breed hardware, it also allows us to integrate
the most modern treatment modalities such as MLC and IMRT
treatments directly with the electronic patient record. Further,
it allows us the freedom to consider integrating future emerging
modalities regardless of vendor.”
IMPAC was founded in 1990 to develop an integrated clinical and
administrative management system tailored specifically for cancer
care and now has more than 2500 installations in 56 countries
worldwide – including over half of the top North American cancer
centres. IMPAC’s oncology information solution is currently the
only system available that is scalable to accommodate both
radiotherapy and chemotherapy data all through a single
application, providing oncologists with a comprehensive view of
the critical data needed to maximize patient care.
IMPAC’s radiotherapy practice management, imaging, and integrated
verify & record solution will be on display at the annual European
Society for Therapeutic Radiology and Oncology (ESTRO) meeting in
Amsterdam, The Netherlands from October 24 - 28, 2004.
About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc. is a
leading provider of oncology IT solutions that streamline both
clinical and business operations to help improve the process of
delivering quality patient care. With systems designed for
anatomic pathology, medical oncology, radiation oncology, imaging,
clinical laboratory, and cancer registry, IMPAC supports the
entire team of healthcare professionals who contribute to the care
of the cancer patient. Supporting more than 2500 installations
worldwide, IMPAC provides practical solutions that deliver better
overall communication, process efficiency and quality patient
care. For more information about IMPAC products and services,
please call +1-650-623-8800 or visit www.impac.com.
The statements contained in this press
release that are not purely historical are forward looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, including statements regarding the Company's
expectations, beliefs, hopes, intentions or strategies regarding
the future. Forward looking statements include statements
regarding the Company's review of its revenue recognition policies
and the estimated impact of the proposed financial restatement of
previously report results, possible delisting from The NASDAQ
Stock Market, business strategy, timing of, and plans for, the
introduction of new products and enhancements, future sales,
market growth and direction, competition, market share, revenue
growth, operating margins and profitability. All forward looking
statements included in this document are based upon information
available to the Company as of the date hereof, and the Company
assumes no obligation to update any such forward looking
statement. Actual results could differ materially from the
Company's current expectations. Factors that could cause or
contribute to such differences include the Company's ability to
expand outside the radiation oncology market or expand into
international markets, our inability to recognize revenue from
multiple element software contracts where certain elements have
been delivered, installed and accepted but other elements remain
undelivered, lost sales or lower sales prices due to competitive
pressures, the ability to integrate its products successfully with
related products and systems in the medical services industry,
reliance on distributors and manufacturers of oncology equipment
to market its products, changes in Medicare reimbursement
policies, the integration and performance of acquired businesses,
and other factors and risks discussed in the 10 K/A and other
reports filed by the Company from time to time with the Securities
and Exchange Commission. |
